Royal Bank Of Canada Reaffirms Buy Rating for Core Laboratories N.V. (NYSE:CLB)

Royal Bank Of Canada reiterated their buy rating on shares of Core Laboratories N.V. (NYSE:CLB) in a report issued on Wednesday, October 18th.

A number of other research analysts have also weighed in on CLB. BidaskClub lowered Core Laboratories N.V. from a sell rating to a strong sell rating in a report on Monday, August 14th. ValuEngine upgraded Core Laboratories N.V. from a sell rating to a hold rating in a report on Friday, August 4th. Morgan Stanley decreased their price objective on Core Laboratories N.V. from $130.00 to $125.00 and set an overweight rating on the stock in a report on Monday, August 7th. Zacks Investment Research lowered Core Laboratories N.V. from a hold rating to a sell rating in a report on Tuesday, September 26th. Finally, Deutsche Bank AG initiated coverage on Core Laboratories N.V. in a report on Tuesday, October 10th. They set a buy rating and a $109.00 price target on the stock. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. Core Laboratories N.V. presently has a consensus rating of Hold and a consensus target price of $108.64.

Shares of Core Laboratories N.V. (NYSE CLB) traded up $3.08 during mid-day trading on Wednesday, reaching $105.28. The company’s stock had a trading volume of 579,691 shares, compared to its average volume of 629,700. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 1.53. The stock has a market cap of $4,511.86, a price-to-earnings ratio of 55.85 and a beta of 1.57. Core Laboratories N.V. has a 12 month low of $86.55 and a 12 month high of $125.83.

Core Laboratories N.V. (NYSE:CLB) last announced its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.04. The company had revenue of $166.20 million for the quarter, compared to analyst estimates of $160.94 million. Core Laboratories N.V. had a return on equity of 52.89% and a net margin of 12.06%. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.38 EPS. equities research analysts predict that Core Laboratories N.V. will post 1.99 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Royal Bank Of Canada Reaffirms Buy Rating for Core Laboratories N.V. (NYSE:CLB)” was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://baseballnewssource.com/markets/royal-bank-of-canada-reaffirms-buy-rating-for-core-laboratories-n-v-clb/1723132.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 21st. Investors of record on Friday, October 20th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.09%. The ex-dividend date is Thursday, October 19th. Core Laboratories N.V.’s payout ratio is 126.44%.

Large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Core Laboratories N.V. during the 2nd quarter worth about $474,000. Goldman Sachs Group Inc. grew its position in Core Laboratories N.V. by 156.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 68,823 shares of the oil and gas company’s stock valued at $7,951,000 after acquiring an additional 41,955 shares in the last quarter. Parsons Capital Management Inc. RI grew its position in Core Laboratories N.V. by 15.4% in the 1st quarter. Parsons Capital Management Inc. RI now owns 10,436 shares of the oil and gas company’s stock valued at $1,206,000 after acquiring an additional 1,394 shares in the last quarter. Morgan Stanley grew its position in Core Laboratories N.V. by 17.5% in the 1st quarter. Morgan Stanley now owns 167,465 shares of the oil and gas company’s stock valued at $19,346,000 after acquiring an additional 24,929 shares in the last quarter. Finally, Cue Financial Group Inc. grew its position in Core Laboratories N.V. by 11.0% in the 2nd quarter. Cue Financial Group Inc. now owns 2,525 shares of the oil and gas company’s stock valued at $256,000 after acquiring an additional 250 shares in the last quarter.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Analyst Recommendations for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.